CD4 and myeloid sarcoma: Regarding targets of autoantibodies identified in MS such as KIR4.1 (25) and anoctamin 2 (26), it will be important to examine whether these autoantigens are also recognized by autoreactive CD4+ T cells and if further evidence supports their pathogenetic relevance before including them in tolerization trials.